<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945553</url>
  </required_header>
  <id_info>
    <org_study_id>M16-609</org_study_id>
    <nct_id>NCT02945553</nct_id>
  </id_info>
  <brief_title>Prevention of Skeletal Muscle Adaptations to Traumatic Knee Injury and Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traumatic knee injury is common and highly debilitating. Surgical reconstruction/repair&#xD;
      improves knee biomechanics and function, but neuromuscular dysfunction persist for years&#xD;
      despite rehabilitation, hindering resumption of normal activities, increasing risk of further&#xD;
      injury and, in a majority of patients, hastening the development of knee osteoarthritis (OA).&#xD;
      Our goal in this research study is to evaluate the utility of neuromuscular electrical&#xD;
      stimulation (NMES), initiated following injury and maintained through the early post-surgical&#xD;
      period, to prevent muscle atrophy and intrinsic contractile dysfunction compared to active&#xD;
      control intervention of micro-electrical stimulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cross-sectional Area of Skeletal Muscle Fibers (All Fibers)</measure>
    <time_frame>Difference between injured and non-injured leg at 3 weeks post-surgery</time_frame>
    <description>Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal Calcium-activated Tension Single Muscle Fiber Tension (Myosin Heavy Chain (MHC) IIA Fibers)</measure>
    <time_frame>Difference between injured and non-injured leg at 3 weeks post-surgery</time_frame>
    <description>Tension (force per unit muscle fiber cross-sectional area) from segments of chemically-skinned single human muscle fibers will be assessed under maximal calcium-activated condition, with muscle fiber type determined post-measurement by gel electrophoresis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal Single Muscle Fiber Shortening Velocity (Myosin Heavy Chain (MHC) IIA Fibers)</measure>
    <time_frame>Difference between injured and non-injured leg at 3 weeks post-surgery</time_frame>
    <description>Maximal shortening velocity from segments of chemically-skinned single human muscle fibers will be assessed, with muscle fiber type determined post-measurement by gel electrophoresis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cross-sectional Area of Skeletal Muscle Fibers (Myosin Heavy Chain (MHC) I Fibers)</measure>
    <time_frame>Difference between injured and non-injured leg at 3 weeks post-surgery</time_frame>
    <description>Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cross-sectional Area of Skeletal Muscle Fibers (MHC IIA)</measure>
    <time_frame>Difference between injured and non-injured leg at 3 weeks post-surgery</time_frame>
    <description>Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Extensor Peak Isokinetic Torque</measure>
    <time_frame>Difference between injured and non-injured leg at 6 months post-surgery</time_frame>
    <description>Peak isokinetic torque is measures in injured and non-injurd leg at 60 deg/s using dynamometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Anterior Cruciate Ligament Reconstruction</condition>
  <arm_group>
    <arm_group_label>NMES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neuromuscular electrical stimulation (NMES) group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microstimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Microstimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuromuscular electrical stimulation</intervention_name>
    <description>Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.</description>
    <arm_group_label>NMES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microstimulation</intervention_name>
    <description>Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.</description>
    <arm_group_label>Microstimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-50 yrs&#xD;
&#xD;
          -  BMI &lt;35 kg/m2&#xD;
&#xD;
          -  acute, first-time, ACL rupture with or without meniscus injury&#xD;
&#xD;
          -  scheduled to undergo reconstruction with a BPTB autograft&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of prior knee/lower extremity surgery or non-surgical intervention (eg,&#xD;
             intra-articular injection) on either leg&#xD;
&#xD;
          -  abnormal laxity of any lower extremity ligament other than the injured ACL&#xD;
&#xD;
          -  signs or symptoms of arthritis, autoimmune or inflammatory disease or diabetes&#xD;
&#xD;
          -  grade IIIb or greater articular cartilage lesions (ICRS criteria)&#xD;
&#xD;
          -  women who are/plan on becoming pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Toth, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce D. Beynnon, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Vermont College of Medicine</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <results_first_submitted>November 12, 2020</results_first_submitted>
  <results_first_submitted_qc>January 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <last_update_submitted>January 1, 2021</last_update_submitted>
  <last_update_submitted_qc>January 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Michael J. Toth, Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Research data (deidentified) which documents, supports and validates research findings will be stored on the University of Vermont College of Medicine computer system and will be made available upon final acceptance for publication of the major findings from the proposed studies. This includes raw data generated from all clinical and laboratory-based assessments under a data-sharing agreement.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02945553/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02945553/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment started in October 2016 and ended in December 2018. Patients were enrolled from an academic orthopedic surgical clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>NMES</title>
          <description>Neuromuscular electrical stimulation (NMES) group&#xD;
Neuromuscular electrical stimulation: Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.</description>
        </group>
        <group group_id="P2">
          <title>Microstimulation</title>
          <description>Microstimulation&#xD;
Microstimulation: Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11">Included in analysis for primary aim.</participants>
                <participants group_id="P2" count="9">Included in analysis for primary aim.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Three (3) patients in NMES and two (2) patients in microstimulation groups were lost to follow-up for analyses of primary aim.</population>
      <group_list>
        <group group_id="B1">
          <title>NMES</title>
          <description>Neuromuscular electrical stimulation (NMES) group&#xD;
Neuromuscular electrical stimulation: Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.</description>
        </group>
        <group group_id="B2">
          <title>Microstimulation</title>
          <description>Microstimulation&#xD;
Microstimulation: Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Injury</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ACL rupture only</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ACL rupture + Meniscus injury</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ACL rupture + Meniscus injury + Cartilage injury</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Exclusion found at surgery (Avulsion)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Withdrew prior to surgery</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ACL rupture + Cartilage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cross-sectional Area of Skeletal Muscle Fibers (All Fibers)</title>
        <description>Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types</description>
        <time_frame>Difference between injured and non-injured leg at 3 weeks post-surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NMES</title>
            <description>Neuromuscular electrical stimulation (NMES) group&#xD;
Neuromuscular electrical stimulation: Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.</description>
          </group>
          <group group_id="O2">
            <title>Microstimulation</title>
            <description>Microstimulation&#xD;
Microstimulation: Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Cross-sectional Area of Skeletal Muscle Fibers (All Fibers)</title>
          <description>Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types</description>
          <units>micrometer squared</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-injured leg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2827" spread="141"/>
                    <measurement group_id="O2" value="3318" spread="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injured leg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2206" spread="125"/>
                    <measurement group_id="O2" value="2376" spread="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Mixed model analysis of variance</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1596</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>202</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximal Calcium-activated Tension Single Muscle Fiber Tension (Myosin Heavy Chain (MHC) IIA Fibers)</title>
        <description>Tension (force per unit muscle fiber cross-sectional area) from segments of chemically-skinned single human muscle fibers will be assessed under maximal calcium-activated condition, with muscle fiber type determined post-measurement by gel electrophoresis</description>
        <time_frame>Difference between injured and non-injured leg at 3 weeks post-surgery</time_frame>
        <population>Difference in sample size in NMES group is due to the fact that one volunteer did not have sufficient tissue to allow assessment of muscle fiber mechanical properties.</population>
        <group_list>
          <group group_id="O1">
            <title>NMES</title>
            <description>Neuromuscular electrical stimulation (NMES) group&#xD;
Neuromuscular electrical stimulation: Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.</description>
          </group>
          <group group_id="O2">
            <title>Microstimulation</title>
            <description>Microstimulation&#xD;
Microstimulation: Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Calcium-activated Tension Single Muscle Fiber Tension (Myosin Heavy Chain (MHC) IIA Fibers)</title>
          <description>Tension (force per unit muscle fiber cross-sectional area) from segments of chemically-skinned single human muscle fibers will be assessed under maximal calcium-activated condition, with muscle fiber type determined post-measurement by gel electrophoresis</description>
          <population>Difference in sample size in NMES group is due to the fact that one volunteer did not have sufficient tissue to allow assessment of muscle fiber mechanical properties.</population>
          <units>mN/mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injured leg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" spread="7"/>
                    <measurement group_id="O2" value="137" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-injured leg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169" spread="7"/>
                    <measurement group_id="O2" value="175" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximal Single Muscle Fiber Shortening Velocity (Myosin Heavy Chain (MHC) IIA Fibers)</title>
        <description>Maximal shortening velocity from segments of chemically-skinned single human muscle fibers will be assessed, with muscle fiber type determined post-measurement by gel electrophoresis</description>
        <time_frame>Difference between injured and non-injured leg at 3 weeks post-surgery</time_frame>
        <population>Difference in sample size in NMES group is due to the fact that one volunteer did not have sufficient tissue to allow assessment of muscle fiber mechanical properties.</population>
        <group_list>
          <group group_id="O1">
            <title>Microstimulation</title>
            <description>Sham control group</description>
          </group>
          <group group_id="O2">
            <title>Neuromuscular Electrical Stimlulation</title>
            <description>Treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Single Muscle Fiber Shortening Velocity (Myosin Heavy Chain (MHC) IIA Fibers)</title>
          <description>Maximal shortening velocity from segments of chemically-skinned single human muscle fibers will be assessed, with muscle fiber type determined post-measurement by gel electrophoresis</description>
          <population>Difference in sample size in NMES group is due to the fact that one volunteer did not have sufficient tissue to allow assessment of muscle fiber mechanical properties.</population>
          <units>muscle length per second (ML/s)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injured leg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.1"/>
                    <measurement group_id="O2" value="1.67" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-injured leg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread=".09"/>
                    <measurement group_id="O2" value="1.92" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cross-sectional Area of Skeletal Muscle Fibers (Myosin Heavy Chain (MHC) I Fibers)</title>
        <description>Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types</description>
        <time_frame>Difference between injured and non-injured leg at 3 weeks post-surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Microstimulation</title>
            <description>Microstimulation: Sham control group</description>
          </group>
          <group group_id="O2">
            <title>Neuromuscular Electrical Stimlulation</title>
            <description>Neuromuscular electrical stimulation: Treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Cross-sectional Area of Skeletal Muscle Fibers (Myosin Heavy Chain (MHC) I Fibers)</title>
          <description>Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types</description>
          <units>micrometer squared</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injured leg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2552" spread="134"/>
                    <measurement group_id="O2" value="2206" spread="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-injured leg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3217" spread="151"/>
                    <measurement group_id="O2" value="2827" spread="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cross-sectional Area of Skeletal Muscle Fibers (MHC IIA)</title>
        <description>Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types</description>
        <time_frame>Difference between injured and non-injured leg at 3 weeks post-surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Microstimulation</title>
            <description>Microstimulation: Sham control group</description>
          </group>
          <group group_id="O2">
            <title>Neuromuscular Electrical Stimlulation</title>
            <description>Neuromuscular electrical stimulation: Treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Cross-sectional Area of Skeletal Muscle Fibers (MHC IIA)</title>
          <description>Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types</description>
          <units>micrometer squared</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injured leg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2290" spread="170"/>
                    <measurement group_id="O2" value="2206" spread="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-injured leg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3739" spread="217"/>
                    <measurement group_id="O2" value="3318" spread="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Knee Extensor Peak Isokinetic Torque</title>
        <description>Peak isokinetic torque is measures in injured and non-injurd leg at 60 deg/s using dynamometry</description>
        <time_frame>Difference between injured and non-injured leg at 6 months post-surgery</time_frame>
        <population>Difference in number of volunteers in analysis is due to loss of patients during 6-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Microstimulation</title>
            <description>Microstimulation: Sham control group</description>
          </group>
          <group group_id="O2">
            <title>Neuromuscular Electrical Stimlulation</title>
            <description>Neuromuscular electrical stimulation: Treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Extensor Peak Isokinetic Torque</title>
          <description>Peak isokinetic torque is measures in injured and non-injurd leg at 60 deg/s using dynamometry</description>
          <population>Difference in number of volunteers in analysis is due to loss of patients during 6-month follow-up.</population>
          <units>% (injured to non-injured leg)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" spread="7.5"/>
                    <measurement group_id="O2" value="66.4" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>30</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months post-surgery</time_frame>
      <desc>Adverse event - any untoward or unfavorable medical occurrence, including any abnormal sign (e.g. abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participants' involvement in the research, whether or not considered related to participation in the research.</desc>
      <group_list>
        <group group_id="E1">
          <title>Microstimulation</title>
          <description>Microstimulation: Sham control group</description>
        </group>
        <group group_id="E2">
          <title>Neuromuscular Electrical Stimlulation</title>
          <description>Neuromuscular electrical stimulation: Treatment group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Re-injury of ACL (graft failure)</sub_title>
                <description>Patient re-injured ACL/tore ACL graft several weeks after completing final study assessments while engaging in sporting activity.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Re-injury of meniscus</sub_title>
                <description>Patient re-injured damaged meniscus during 6-month post-surgery follow-up.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Patient experienced muscle strain during muscle strength assessment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Procedural complication.</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Patient developed rash related to antiseptic used during muscle biopsy procedure.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Toth</name_or_title>
      <organization>University of Vermont College of Medicine</organization>
      <phone>802-656-7989</phone>
      <email>michael.toth@med.uvm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

